Reduced risk for chronic myelogenous leukemia in individuals with the cytochrome P-450 gene polymorphism CYP1A1*2A

Blood

Volumn 98, Issue 13, 2001, Pages 3874-3875

  Löffler, Harald ^a   Bergmann, Jörg ^a   Hochhaus, Andreas ^a   Hehlmann, Rüdiger ^a   Krämer, Alwin ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER RISK; CHRONIC MYELOID LEUKEMIA; CYP1A1 2A GENE; ENZYME POLYMORPHISM; GENE; GENE DELETION; GENE FREQUENCY; GENETIC SUSCEPTIBILITY; HUMAN; LETTER; PRIORITY JOURNAL;

EID: 0035895090     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.V98.13.3874     Document Type: Letter

References (5)

1. Perera FP. Environment and cancer: who are susceptible? Science. 1997;278:1068-1073.
2. Smith CAD, Gough AC, Leigh PN, et al. Debrisoquine hydroxylase gene polymorphism and susceptibility to Parkinson's disease, Lancet. 1992;339:1375-1377.
3. Kawajiri K, Eguchi H, Nakachi K, Sekiya T, Yamamoto M. Association of CYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res. 1996;56:72-76.
4. Krajinovic M, Labuda D, Richer C, Karimi S, Sinnett D. Susceptibility to childhood acute lymphoblastic leukemia: influence of CYP1A1, CYP2D6, GSTM1, and GSTT1 genetic polymorphisms. Blood. 1999;93:1496-1501.
5. Chen H, Sandier DP, Taylor JA, et al. Increased risk for myelodysplastic syndromes in individual with glutathione transferase theta 1 (GSTT1) gene defect. Lancet. 1996;347:295-297.